A Phase I trial of RDX8940.
Latest Information Update: 22 Feb 2017
Price :
$35 *
At a glance
- Drugs RDX 8940 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- 22 Feb 2017 New trial record
Latest Information Update: 22 Feb 2017